New York Genome Center reposted this
Saunders Family Chair and Professor of Neurology at the Icahn School of Medicine at Mount Sinai
"Researchers have discovered a genetic variant that reduces the odds of developing #AlzheimersDisease by up to 70% and may be protecting thousands of people in the United States from the disease." "The discovery of the protective variant, which appears to allow toxic forms of #Amyloid out of the brain and through the #BloodBrainBarrier, supports emerging evidence that the brain’s blood vessels play a large role in #Alzheimers disease and could herald a new direction in therapeutic development." Learn More in Acta Neuropathologica: Pathology and Mechanisms of Neurological Disease https://lnkd.in/dkNm-CNt Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease - Prabesh Bhattarai, PhD, Tamil Iniyan Gunasekaran, Richard Mayeux, Caghan Kizil, Badri Vardarajan, et al. Columbia University Irving Medical Center, Columbia University Taub Institute on Alzheimer’s Disease and the Aging Brain Gertrude H. Sergievsky Center, Columbia University Vagelos College of Physicians and Surgeons Stanford University Washington University School of Medicine in St. Louis Yale University The Henry M. Jackson Foundation for the Advancement of Military Medicine Pontificia Universidad Católica Madre y Maestra CEDIMAT, Plaza de la Salud, Santo Domingo Universidad Pedro Henríquez Ureña (UNPHU) MAYO CLINIC FLORIDA Center for Military Precision Health, Uniformed Services University New York Genome Center Columbia University Mailman School of Public Health https://lnkd.in/dxcSqn2w
I previously found that fibronectin binds to amyloid beta. I could pull it down using Lecanemab.
This seems like a potentially groundbreaking finding in better understanding the genetic factors and mechanisms underlying Alzheimer's. Identifying a rare variant that reduces risk by up to 70% is remarkable and provides valuable insights. I'm interested to see how this line of research progresses and if it does indeed spark the development of novel vascular-targeted therapies.
Life Science #Patent Agent at #Honigman LLP
3moDo people with this fibronectin variant bruise more easily, or is this variant only expressed in the brain? Also, this supports the finding that people that begin taking low-dose aspirin in midlife have significantly reduced risk of vascular dementia which is part in parcel of AD. The aspirin study is the first study to look at the effect of administering aspirin in people ages 55 and older for at least 10 years. The other randomization placebo controlled studies were testing whether aspirin can reverse dementia — no it cannot. https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01017-4